Core Viewpoint - The outbreak of Nipah virus in West Bengal, India, highlights the urgent need for rapid and accurate diagnostic and warning capabilities in global public health systems, with the infection fatality rate reaching 40% to 75% and no specific treatment or vaccine available [1] Group 1: Company Overview - Huajian Medical is a high-tech intellectual property capital operation platform focused on the life sciences sector, closely monitoring global public health dynamics and providing technical support for infectious disease prevention and control [1] - The company’s subsidiary, Shenzhen Carbon Hua Biotechnology Co., Ltd., specializes in molecular diagnostics and aims to provide comprehensive solutions in this field [1] Group 2: Technological Advancements - Carbon Hua has developed a dual-platform detection solution for Nipah virus, which includes a rapid screening platform and a high-throughput sequencing and intelligent analysis platform [2] - The intelligent fluorescence PCR rapid detection platform utilizes an AI primer design platform to efficiently identify and lock onto conserved gene regions of high-risk pathogens, ensuring high specificity and sensitivity in detection [2] - The high-throughput sequencing and intelligent analysis platform offers a localized sequencing solution that can detect and differentiate Nipah virus and other co-existing pathogens, completing the process from sample receipt to report generation within 17 hours [3] Group 3: Strategic Implications - The rapid response to Nipah virus detection demonstrates the integrated technical capabilities of Huajian Medical in public health emergencies and marks a significant step in advancing the company's AI medical strategy [3] - The company aims to establish a replicable intelligent public health monitoring system adaptable to various emerging infectious diseases and chronic disease management scenarios [4] - The product launch and strategic outline reflect the company's commitment to the core paradigm of "intelligent capital driving continuous knowledge profitability" [4]

1月27日晚间，华大基因发布2025年度业绩预告。业绩预告显示，公司2025年营业收入预计为36亿元至 39亿元，归母净利润同比大幅减亏。 华大基因表示，业绩变动主要受行业竞争加剧导致部分产品毛利率下降幅度较大、客户回款周期延长带 来的信用减值损失增加，以及对部分交付中心进行战略调整所计提的资产减值等因素影响。 值得注意的是，华大基因通过精益运营有效控制费用，销售、管理及研发费用同比均实现较大幅度下 降，体现出较强的成本管控能力。同时华大基因表示，将加强信用管控和加大催收力度，目前正在通过 诉讼、以物抵债等多种途径进行应收账款管理，力争应收余额和账期控制在合理水平。 尽管短期业绩承压，但华大基因各业务在产品结构优化与场景落地方面取得显著进展。具体来看，2025 年，华大基因生育健康业务营收有所下降，主要受出生人口减少及集采政策影响，无创产前基因检测样 本量及产品价格同比下滑。不过另一方面，华大基因也在持续加强生育健康业务入院布局，院内销售的 试剂收入列入精准医学综合解决方案板块。为应对无创产前检测基础版产品价格下降的风险，华大基因 推动无创产前检测全因系列等高毛利产品的布局，以优化业务结构。与此同时，公司在三 ...

北京商报讯（记者 丁宁）1月27日晚间，华大基因（300676）发布2025年度业绩预告显示，公司2025年 预计实现归属净利润-5.3亿元至-6.3亿元，上年同期为-9.03亿元，同比出现减亏。 华大基因表示，受市场需求波动及行业竞争加剧影响，公司终端服务/产品价格进一步下降，部分产品 毛利率较上年同期下降幅度较大。公司继续主动战略性调整主营业务产品结构，聚焦核心优势产品线经 营，推进主营业务稳步发展。公司持续推进降本增效，通过精益运营，在费用端实现有效管控，预计销 售费用、管理费用、研发费用同比实现较大幅度下降。 ...

Core Insights - Significant advancements have been made in xenotransplantation, with successful clinical cases reported for organs such as the heart, kidneys, liver, and lungs, particularly by research teams in China, raising hopes for the future of this field [1][8] - Although xenotransplantation is still in its early stages and long-term safety and efficacy remain unverified, successful implementation could effectively address organ shortages, providing new treatment options for thousands of patients awaiting transplants [8] Group 1: Research Findings - A recent paper published in *Nature Medicine* by a research team from Massachusetts General Hospital analyzed the immune landscape of the world's first patient receiving a pig kidney xenotransplant, revealing persistent activation of innate immunity despite immunosuppressive strategies [8] - The patient, a 62-year-old man with type 2 diabetes and hypertension, underwent surgery on March 16, 2024, after experiencing kidney failure following a previous transplant [4][11] - The pig kidney used for the xenotransplant was sourced from eGenesis, which edited 69 genes in the pig, including knocking out 59 endogenous retrovirus genes and introducing 7 human genes [4][11] Group 2: Immune Response Analysis - The patient exhibited an immune rejection response on the 8th day post-transplant, with immune profiling continuing until day 51, showing a significant decrease in adaptive immune cells while innate immune cells remained elevated [6][12] - The innate immune response was characterized by the activation of various pathways, particularly the NF-κB and IFN-I signaling axes, leading to sustained activation of monocytes/macrophages and increased production of multiple cytokines [12] - The study found that the level of donor-derived cell-free DNA (dd-cfDNA) surged approximately 1000 times during rejection, indicating graft damage, and suggested that dd-cfDNA could serve as a non-invasive biomarker for immune monitoring or therapeutic strategy development [7][12]

华大基因1月27日公告，预计2025年度实现归属于上市公司股东的净利润为亏损5.3亿元至6.3亿元，上年 同期亏损9.03亿元。 华大基因1月27日公告，预计2025年度实现归属于上市公司股东的净利润为亏损5.3亿元至6.3亿元，上年 同期亏损9.03亿元。 ...

南财智讯1月27日电，华大基因发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为-63,000万元至-53,000万元，即净亏损5.30亿元—6.30亿元；预计2025年全年归属于上市公司股东的扣 除非经常性损益的净利润为-67,500万元至-54,500万元。业绩变动原因说明：（一）预计公司2025年度 营业收入约360,000万元至390,000万元，较上年同期变动幅度为-6.90%～0.86%，预计公司2025年归属于 上市公司股东的净利润约-63,000万元至-53,000万元。业绩变动的主要原因如下：1、受市场需求波动及 行业竞争加剧影响，公司终端服务/产品价格进一步下降，部分产品毛利率较上年同期下降幅度较大。 公司继续主动战略性调整主营业务产品结构，聚焦核心优势产品线经营，推进主营业务稳步发展。公司 生育健康业务营业收入较2024年同期有所下降，主要系市场需求下降、集采政策陆续实施所致，无创产 前基因检测样本量及产品价格同比下滑，公司持续加强生育健康业务入院布局，院内销售的试剂收入列 入在精准医学综合解决方案板块。同时，公司将进一步推动无创产前检测全因系列等高毛利产品的布局 以应对 ...

华大基因公告称，2025年预计营业收入36-39亿元，较上年同期变动-6.90%~0.86%；归属于上市公司股 东的净利润-6.3- -5.3亿元，上年同期亏损9.03亿元。业绩变动主因市场需求波动、行业竞争加剧，部分 产品毛利率下降。公司主动调整业务结构，各业务板块有不同表现。此外，客户回款周期延长致信用减 值损失增加，部分交付中心战略调整计提减值准备，不过费用端实现有效管控。非经常性损益影响约 1500-4500万元。 ...

Group 1 - The 19th Asian Financial Forum, co-hosted by the Hong Kong SAR government and the Hong Kong Trade Development Council, introduced the "Global Industry Summit" focusing on high-growth and high-value sectors such as biomedicine and healthcare [1] - Junshi Biosciences, a key exhibitor in the biomedicine sector, showcased its technological breakthroughs, product pipeline, and commercialization prospects in the TIL (tumor-infiltrating lymphocyte) therapy field [1] - The company submitted its listing application to the Hong Kong Stock Exchange in December last year and has completed multiple financing rounds totaling nearly 800 million RMB, with a recent C round completed in November 2025, achieving a valuation of 2.137 billion RMB [1] Group 2 - Junshi Biosciences' core product, GC101, is the world's first natural TIL cell new drug that does not require high-intensity lymphodepletion chemotherapy or IL-2 administration, providing long-term benefits to patients with advanced metastatic solid tumors [2] - The product has shown complete tumor clearance in multiple patients, with the longest progression-free survival exceeding 4 years [2] - The company is also actively developing the world's first in-vivo TIL therapy, aiming to shift TIL therapy from a "highly personalized" to a "quasi-off-the-shelf" model, significantly reducing production costs and patient wait times, thereby enhancing accessibility [2]

全球领先的数字金融基础设施建设者华赢集团AlloyX Group(AXG.US)今日宣布，已与美国知名生物科 技公司Bricopia Inc. 正式签署战略合作协议。双方将共同推出全球首个"基于合规架构推进的"生物资产 数字化项目，标志着生命科学资产正式进入"通证化"的新纪元。 近年来，现实世界资产数字化受到机构和监管的持续关注。此次合作旨在通过区块链技术，将Bricopia 拥有的高价值生物资产转化为可合规交易、透明溯源的数字证券。作为本次合作的技术与合规推动者， AXG将运用其在资产上链、数字证券化方面的深厚积淀，为Bricopia提供全栈式数字资产解决方案。 ...

山东中农联合生物科技股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、股票交易异常波动的情况介绍 山东中农联合生物科技股份有限公司（证券简称：中农联合，证券代码：003042，以下简称"公 司"或"本公司"）股票于2026年1月23日、2026年1月26日连续2个交易日收盘价格涨幅偏离值累计超过 20%，根据《深圳证券交易所交易规则》的相关规定，属于股票交易异常波动的情况。 二、公司关注并核实情况的说明 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：003042 证券简称：中农联合 公告编号：2026-004 针对公司股票交易异常波动，公司对有关事项进行了核查，并对控股股东及实际控制人就相关事项进行 了核实，现就有关情况说明如下： 1、公司前期披露的信息不存在需要补充、更正之处。 2、公司未发现公共传媒报道了可能或已经对本公司股票交易价格产生较大影响的未公开重大信息。 3、近期公司生产经营情况正常，内外部经营环境未发生重大变化。 4、经核查，公司及控股股东、实际控制人不存在应披露而未披露的重大事项，也不存在处 ...